Myriad Genetics soars 65% following InvestingPro's May fair value alert

InvestingPro's Fair Value model accurately identified Myriad Genetics (MYGN) as significantly undervalued in May 2025 at $3.84, preceding a 65% stock surge to $6.32 within three months. This validation was driven by MYGN's operational improvements, including narrowed EBITDA losses from -$29.2 million to -$17.8 million, a Q2 2025 earnings beat, and a new $200 million credit facility. The case highlights the efficacy of sophisticated, data-driven valuation methodologies in uncovering market inefficiencies and generating substantial returns.

Analysis

Myriad Genetics (MYGN) has undergone a significant re-rating, with its stock appreciating 65% to $6.32 over a three-month period following a valuation call in mid-May 2025. This surge was preceded by a six-month period of consistent declines, which pushed the stock to $3.84 despite the company generating $831.3 million in trailing revenue. The reversal was driven by tangible improvements in the company's fundamentals, including a Q2 2025 earnings report that exceeded expectations and prompted management to raise guidance. Operationally, Myriad has demonstrated a positive trajectory by narrowing its EBITDA loss from -$29.2 million to -$17.8 million. The company's financial position was also materially strengthened by securing a new $200 million credit facility, which provides enhanced liquidity to support its operations and growth initiatives.

Key Decisions for Investors

• Given the stock's 65% rally, investors should recognize that the significant valuation disconnect identified in May has now substantially closed, warranting a re-evaluation of the risk/reward profile at the current price of $6.32.
• Sustained momentum is now critical; therefore, closely monitor upcoming quarterly reports for continued evidence of narrowing EBITDA losses and revenue growth acceleration to justify the stock's higher valuation.
• While the new $200 million credit facility improves the company's liquidity position, it is crucial to assess the cash burn rate and the timeline to profitability to ensure the capital is sufficient to bridge the gap to self-sustaining operations.